Skip to main content
NCBI home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(2):148–152. doi: 10.1111/j.1349-7006.2003.tb01411.x

Polo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancers

Takao Takahashi 1,3, Bun Sano 1, Takayasu Nagata 1, Hiroki Kato 1, Yasuyuki Sugiyama 1, Katsuyuki Kunieda 1, Masashi Kimura 2, Yukio Okano 2, Shigetoyo Saji 1,4
PMCID: PMC11160284  PMID: 12708489

Abstract

PLK (polo‐like kinase), the human counterpart of polo in Drosophila melanogaster and of CDC5 in Saccharomyces cerevisiae, belongs to a family of serine/threonine kinases. It is intimately involved in spindle formation and chromosome segregation during mitosis. The purpose of this study was to determine whether PLK1 is overexpressed in primary colorectal cancer specimens as compared with normal colon mucosa and to assess its relation to other kinases as a potential new tumor marker. In the present study, immunohistochemical analyses were performed of PLK1 expression in 78 primary colorectal cancers as well as 15 normal colorectal specimens. Furthermore, we examined the relationship between other kinases, Aurora‐A and Aurora‐C, and PLK1 expression. In normal colon mucosa, some crypt cells showed weakly positive staining for PLK1 in 13 out of 15 cases, the remaining cases being negative. Elevated expression of PLK1 was observed in 57 (73.1%) of the colorectal cancers, statistically significant associations being evident with pT (primary tumor invasion) (P=0.0006, Mann‐Whitney U test), pN (regional lymph nodes) (P=0.008, χ2 test) and the Dukes' classification (P=0.0005, Mann‐Whitney U test). Mean proliferating cell nuclear antigen‐labeling index was 52.3%, with a range of 24.1% to 77.3%. Values for lesions with high and low PLK1 expression were 54.7±10.3% (mean$MpSD) and 45.9$Mp11.9% (P=0.002, Student's t test). PLK1 was significantly associated with Aurora‐A, but PLK1 staining was more diffuse and extensive than for Aurora‐A or Aurora‐C. Interestingly, PLK1 overexpression was significantly associated with p53 accumulation in colorectal cancers. Our results suggest over‐expression of PLK1 might be of pathogenic, prognostic and proliferative importance, so that this kinase might have potential as a new tumor marker for colorectal cancers. (Cancer Sci 2003; 94: 148–152)

References

  • 1. Perkins AS, Stern DF. Molecular biology of cancer: oncogenes. In: De Vita VT Jr, Hellman SA, editors. Rosenberg cancer: principles & practices of oncology. 5th ed. Philadelphia : Lippincott‐Raven Publ; 1997. p. 79–102. [Google Scholar]
  • 2. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during col‐orectal‐tumor development. N Engl J Med 1988; 319: 525–32. [DOI] [PubMed] [Google Scholar]
  • 3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–67. [DOI] [PubMed] [Google Scholar]
  • 4. Takahashi T, Haruki N, Nomoto S, Masuda A, Saji S, Osada H, Takahashi T. Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers. Oncogene 1999; 18: 4295–300. [DOI] [PubMed] [Google Scholar]
  • 5. Nomoto S, Haruki N, Takahashi T, Masuda A, Koshikawa T, Fujii Y, Osada H, Takahashi T. Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers. Oncogene 1999; 18: 7180–3. [DOI] [PubMed] [Google Scholar]
  • 6. Lingle WL, Lutz WH, Ingle JN, Maihle NJ, Salisbury JL. Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc Natl Acad Sci USA 1998; 95: 2950–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P, Doxsey SJ. Centrosome defects and genetic instability in malignant tumors. Cancer Res 1998; 58: 3974–85. [PubMed] [Google Scholar]
  • 8. Salisbury JL, Whitehead CM, Lingle WL, Barrett SL. Centrosomes and cancer. Biol Cell 1999; 91: 451–60. [PubMed] [Google Scholar]
  • 9. Glover DM, Leibowitz MH, McLean DA, Parry H. Mutations in aurora prevent Centrosome separation leading to the formation of monopolar spindles. Cell 1995; 81: 95–105. [DOI] [PubMed] [Google Scholar]
  • 10. Nigg, EA . Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001; 2: 21–32. [DOI] [PubMed] [Google Scholar]
  • 11. Takahashi T, Futamura M, Yoshimi N, Sano J, Katada M, Takagi Y, Kimura M, Yoshioka T, Okano Y, Saji S. Centrosomal kinases, HsAIRK1 and HsAIRK3, are overexpressed in primary colorectal cancers. Jpn J Cancer Res 2000; 91: 1007–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Holtrich U, Wolf G, Brauninger A, Karn T, Bohme B, Rubsamen‐Waigmann H, Strebhardt K. Induction and down‐regulation of PLK, a human serine/ threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 1994; 91: 1736–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Hamanaka R, Maloid S, Smith MR, O'Connell CD, Longo DL, Ferris DK. Cloning and characterization of human and murine homologues of the Drosophila polo serine‐threonine kinase. Cell Growth Differ 1994; 5: 249–57. [PubMed] [Google Scholar]
  • 14. Golsteyn RM, Schultz SJ, Bartek J, Ziemiecki A, Ried T, Nigg EA. Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci 1994; 107: 1509–17. [DOI] [PubMed] [Google Scholar]
  • 15. Nigg EA. Polo‐like kinases: positive regulators of cell division from start to finish. Curr Opin Cell Biol 1998; 10: 776–83. [DOI] [PubMed] [Google Scholar]
  • 16. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rubsamen‐Waigmann H, Strebhardt K. Prognostic significance of polo‐like kinase (PLK) expression in non‐small cell lung cancer. Oncogene 1997; 14: 543–9. [DOI] [PubMed] [Google Scholar]
  • 17. Knecht R, Elez R, Oechler M, Solbach C, Von Ilberg C, Strebhardt K. Prognostic significance of polo‐like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 2794–7. [PubMed] [Google Scholar]
  • 18. Yuan J, Horlin A, Hock B, Stutte HJ, Rubsamen‐Waigmann H, Strebhardt K. Polo‐like kinase, a novel marker for cellular proliferation. Am J Pathol 1997; 150: 1165–72. [PMC free article] [PubMed] [Google Scholar]
  • 19. Dukes CE, Bussey HJR. The spread of rectal cancer and its effect on prognosis. Br J Cancer 1958; 12: 309–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Sobin LH, Wittekind C. TNM classification of malignant tumours. 5th ed. New York : Wiley‐Liss Inc; 1997. p. 66–9. [Google Scholar]
  • 21. Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 1999; 59: 2041–4. [PubMed] [Google Scholar]
  • 22. Golsteyn RM, Mundt KE, Fry AM, Nigg E. Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol 1995; 129: 1617–28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Glover DM, Hagan IM, Tavares AA. Polo‐like kinases: a team that plays throughout mitosis. Genes Dev 1998; 12: 3777–87. [DOI] [PubMed] [Google Scholar]
  • 24. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL, Ferris DK. Malignant transformation of mammalian cells initiated by constitutive expression of the polo‐like kinase. Biochem Biophys Res Commun 1997; 234: 397–405. [DOI] [PubMed] [Google Scholar]
  • 25. Elez R, Piiper A, Giannini CD, Brendel M, Zeuzem S. Polo‐like kinase 1, a new target for antisense tumor therapy. Biochem Biophys Res Commun 2000; 269: 352–6. [DOI] [PubMed] [Google Scholar]
  • 26. Dunican, DS , McWilliam P, Tighe O, Parle‐McDermott A, Croke DT. Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high‐density cDNA array hybridization. Oncogene 2002; 21: 3253–7. [DOI] [PubMed] [Google Scholar]
  • 27. Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y. Prognostic significance of polo‐like kinase expression in esophageal carcinoma. Int J Oncol 1999; 15: 687–92. [DOI] [PubMed] [Google Scholar]
  • 28. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. Expression of polo‐like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett 2001; 164: 41–9. [DOI] [PubMed] [Google Scholar]
  • 29. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. Pololike kinase (PLK) expression in endometrial carcinoma. Cancer Lett 2001; 169:41–9. [DOI] [PubMed] [Google Scholar]
  • 30. Macmillan JC, Hudson JW, Bull S, Dennis JW, Swallow CJ. Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer. Ann Surg Oncol 2001; 8: 729–40. [DOI] [PubMed] [Google Scholar]
  • 31. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo‐like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002; 29: 354–8. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES